Per Lundin

Co-founder & Chief Business Officer @Evox Therapeutics Ltd

Co-founded the company and closed a $13m investment in what was one of the largest European seed rounds of 2016. Crafted a rare disease pipeline-driven platform strategy leveraging foundational intellectual property licensed from two world-leading academic institutions and has been instrumental in all aspects of company building since, including the raising of a $46m Series B and a $95m Series C as well as the signing of two pharmaceutical company partnerships with combined deal values of around $2bn.